

APPENDIX TO SCIENTIFIC REPORT DIAGNOSTIC IMMUNOHISTOCHEMISTRY AND ELECTRON MICROSCOPY TESTING IN BELGIUM SUPPLEMENT



APPENDIX TO SCIENTIFIC REPORT DIAGNOSTIC IMMUNOHISTOCHEMISTRY AND ELECTRON MICROSCOPY TESTING IN BELGIUM SUPPLEMENT

LORENA SAN MIGUEL, CHRISTOPHE DE MEESTER, ELENA COSTA, CLAUDIA SCHÖNBORN



COLOPHON

Title:	Appendix to scientific report diagnostic immunohistochemistry and electron microscopy testing in Belgium – Supplement
Authors:	Lorena San Miguel (KCE), Christophe de Meester (KCE), Elena Costa (KCE), Claudia Schönborn (KCE)
Project facilitator:	Els Van Bruystegem (KCE)
Information specialist:	Nicolas Fairon (KCE)
Data extraction, transformation and loading (ETL)	Cécile Camberlin (KCE)
Reviewers:	Sophie Gerkens (KCE), Vicky Jespers (KCE), Bénédicte Vos (KCE)
External experts and stakeholders:	Marc Bossens (RIZIV – INAMI - Rijksinstituut voor ziekte- en invaliditeitsverzekering – Institut national d'assurance maladie-invalidité), Romaric Croes (Belgian Society of Pathology), Olivier Delhove (SYNLAB Belgium), Annemie Dereymaeker (RIZIV - INAMI), Christine Galant (Cliniques universitaires Saint-Luc), Krista Goorts (RIZIV - INAMI), Martin Lammens (UZA - Universitair Ziekenhuis Antwerpen, Cliniques Universitaires Saint-Luc, Université catholique de Louvain), Francesco Puleo (CHIREC Site Delta), Roberto Salgado (ZNA - Ziekenhuis Netwerk Antwerpen, GZA - Gasthuis Zusters Antwerpen ziekenhuis), Stefan Teughels (Domus Medica), Philippe Volcke (RIZIV - INAMI)
External validators:	Gianmarco Contino (University of Birmingham, United Kingdom), Edwin Heeregrave (Zorginstituut Nederland, the Netherlands), Pascale Quatresooz (Centre Hospitalier Universitaire de Liège)
Acknowledgements:	We would like to thank Joris Arts (Sint-Lucas VZW), Pamela Baldin (UCL, hôpital St Luc), Elettra Bianchi (CHU Liège), Amélie Dendooven (UZ Gent), Stephan Devriese (KCE), Frank Hulstaert (KCE), Valérie Lindecker (HAS - Haute Autorité de Santé, France), Sien Ombelet (KCE), Célia Primus-de Jong (KCE), for their contribution to this study, as well as all participants to our online surveys.
Reported interests KCE members:	KCE is a federal institution funded by INAMI/RIZIV, by the Federal Public Service of Health, Food chain Safety and Environment, and by the Federal Public Service of Social Security. KCE's mission is to advise policymakers on decisions relating to health care and health insurance on the basis of scientific and objective research. It is expected to identify and shed light on the best possible solutions, in the context of an accessible, high-quality health care system with due regard for growing demand and budgetary constraints. KCE has no interest in companies (commercial or non-commercial, i.e. hospitals and universities), associations (e.g. professional associations, unions), individuals or organisations (e.g. lobby groups) that could be positively or negatively affected (financially or in any other way) by the implementation of the recommendations. All experts involved in the writing of the report or the peer-review process completed a declaration of interest form. Information



on potential conflicts of interest is published in the colophon of this report. All members of the KCE Expert Team make yearly declarations of interest and further details of these are available upon request.

Reported interests:

'All experts and stakeholders consulted within this report were selected because of their involvement in the topic of Diagnostic Immunohistochemistry and electron microscopy testing in Belgium. Therefore, by definition, each of them might have a certain degree of conflict of interest to the main topic of this report'

Layout:

Joyce Grijseels

Disclaimer:

- **The external experts were consulted about a (preliminary) version of the scientific report. Their comments were discussed during meetings. They did not co-author the scientific report and did not necessarily agree with its content.**
- **Subsequently, a (final) version was submitted to the validators. The validation of the report results from a consensus or a voting process between the validators. The validators did not co-author the scientific report and did not necessarily all three agree with its content.**
- **Finally, this report has been approved by common assent by the Executive Board.**
- **Only the KCE is responsible for errors or omissions that could persist. The policy recommendations are also under the full responsibility of the KCE.**

Publication date:

30 May 2024, 2nd print: 26/08/2024

Project number:

2021-01-HTA

Domain:

Health Technology Assessment (HTA)

MeSH:

Immunohistochemistry ; Microscopy, Electron ; Diagnosis ; Helicobacter pylori ; Celiac Disease

NLM Classification:

QY 250

Language:

English

Format:

Adobe® PDF™ (A4)

Legal depot:

D/2024/10.273/34

ISSN:

2466-6459

Copyright:

KCE reports are published under a “by/nc/nd” Creative Commons Licence
<http://kce.fgov.be/content/about-copyrights-for-kce-publications>.



How to refer to this document?

San Miguel L, de Meester C, Costa E, Schönborn C. Appendix to scientific report diagnostic immunohistochemistry and electron microscopy testing in Belgium. Health Technology Assessment (HTA) Brussels: Belgian Health Care Knowledge Centre (KCE). 2024. KCE Reports 384S. DOI: <https://doi.org/10.57598/R384S>.

This document is available on the website of the Belgian Health Care Knowledge Centre.



■ APPENDIX REPORT

TABLE OF CONTENTS

■	APPENDIX REPORT	1
	TABLE OF CONTENTS	1
	LIST OF TABLES	2
1.	NOMENCLATURE USED FOR THE SELECTION OF EPS DATA.....	3
2.	INDICATIONS FOR IHC TESTING	8
3.	SURVEY TO ALL BELGIAN LABORATORIES	10
3.1.	IHC STAINS QUESTIONNAIRE (NOMENCLATURE CODES 588070-588081)	10
3.2.	EM EXAMINATIONS QUESTIONNAIRE	10
3.3.	OTHER IHC STAINS CITED BY LABORATORIES.....	11
4.	REVIEWS OF THE LITERATURE	12
4.1.	SEARCH STRATEGIES.....	12
4.1.1.	Cochrane.....	12
4.1.2.	Embase	12
4.1.3.	Medline.....	15
4.2.	PICO H. PYLORI	49
4.3.	PICO COELIAC DISEASE	50
4.4.	PICO EM INDICATIONS	50
5.	QUALITY ASSESSMENT – AGREE II GRD – SUMMARY TABLES.....	52



LIST OF TABLES

Table 1 – nomenclature of stomach biopsies (gastroscopies)	3
Table 2 – nomenclature of non-invasive Helicobacter Pylori tests	3
Table 3 – Nomenclature for anatomopathological acts IHC	4
Table 4 – Most used stained according to the body sites, origin of the prelevement (Non extrapolated numbers).	8
Table 5 – Detail of the other IHC stains cited by laboratories as the 5 most frequent	11
Table 6 – Quality assessment of guidelines included in H. pylori literature review	52
Table 7 – Quality assessment guidelines included in coeliac disease literature review	55
Table 8 – Quality assessment guidelines included in EM literature review	57



1. NOMENCLATURE USED FOR THE SELECTION OF EPS DATA

Table 1 – nomenclature of stomach biopsies (gastrosopies)

Stomach biopsy			Reimbursement per test in 2024
472356 - 472360	Examen de l'oesophage par endoscopie	Onderzoek van de oesophagus door middel van endoscopie	2016-
473056 - 473060	Examen du tube digestif supérieur par endoscopie	Onderzoek van het hogere spijsverteringskanaal door middel van endoscopie	2016-
473093 - 473104	Examen de l'intestin grêle avec un endoscope muni d'un dispositif facilitant sa progression, par voie orale	Onderzoek van de dunne darm met een endoscoop die is uitgerust met een hulpmiddel om het inbrengen ervan langs orale weg te vergemakkelijken	2016-

Table 2 – nomenclature of non-invasive Helicobacter Pylori tests

			Reimbursement per test in 2024
551994 - 552005	Recherche d'anticorps Helicobacter pylori (Maximum 1)(Règle diagnostique 76)	Opzoeken van Helicobacter pylori antilichamen (Maximum 1)(Diagnoseregels 76)	Not yet reimbursed since 01/01/2021
552355 - 552366	Recherche d'antigènes d'Helicobacter pylori (Maximum 1) (Règles diagnostiques 76, 90)	Opzoeken van Helicobacter pylori antigenen (Maximum 1) (Diagnoseregels 76, 90)	6.05€
552370 - 552381	Recherche d'antigènes d'Helicobacter pylori post-traitement (Maximum 1) (Règle diagnostique 91)	Opzoeken van Helicobacter pylori antigenen na behandeling (Maximum 1) (Diagnoseregels 91)	6.05€
473255 - 473266	Mesure d' isotopes stables dans les produits terminaux du métabolisme avec un spectrographe de masse	Meting van stabiele isotopen in de eindproducten van het métabolisme met een massaspectrograaf	146.67€



Table 3 – Nomenclature for anatomopathological acts IHC

Nomenclature code	Description NL	Description FR	Years selected
588232 - 588243	Histologisch onderzoek door inclusie en coupe, ongeacht het aantal coupes en ongeacht het aantal onderzochte organen, en met inbegrip van het eventueel macroscopisch onderzoek van de afnames bij volgende ingrepen: - vagotomie - vasectomie - tuba-ligatuur - tonsillectomie (< 18 jaar) - adenoïdectomie (< 18 jaar) - sympathectomie	Examen histologique par inclusion et coupe, quel que soit le nombre de coupes et quel que soit le nombre d'organes examinés, et ce compris l'examen macroscopique éventuel, pour les prélèvements des interventions suivantes : - vagotomie - vasectomie - ligature tubaire - amygdalectomie (< 18 ans) - adénoïdectomie (< 18 ans) - sympathectomie	
588254 - 588265	Histologisch onderzoek door inclusie en coupe, ongeacht het aantal coupes en ongeacht het aantal onderzochte organen, en met inbegrip van het eventueel macroscopisch onderzoek, van de bipten van volgende diepe organen: - lever - nier - nierbekken - bijnier - prostaat - borst - lymfeklier - beenmerg - bot - schildklier - speekselklier - pleura - long - testikel - peritoneum - retroperitoneum - mediastinum	Examen histologique par inclusion et coupe, quel que soit le nombre de coupes et quel que soit le nombre d'organes examinés, en ce compris l'examen macroscopique éventuel, pour les biopsies des organes profonds suivants: - foie - rein - bassin - surrénale - prostate - sein - ganglion lymphatique - moelle osseuse - os - glande thyroïde - glande salivaire - plèvre - poumon - testicule - péritoine - rétropéritoine - médiastin	



Nomenclature code	Description NL	Description FR	Years selected
	- hersenen en ruggenmerg - hart - pancreas	- cerveau et moelle épinière - coeur - pancréas	
588276 - 588280	Histologisch onderzoek, door inclusie en coupe, ongeacht het aantal coupes en ongeacht het aantal onderzochte organen, en met inbegrip van het eventueel macroscopisch onderzoek, van volgende operatiestukken: - lymfeklierexerese - eenzijdige okselklieruitruiming - eenzijdige liesklieruitruiming - heerkundige longbiopsie voor niet-oncologische indicatie - partiële of totale thymectomie - resectie van subfasciale tumoren - partiële hepatectomie - cholecystectomie - splenectomie - mesenteriale tumorectomie - retroperitoneale tumorectomie - oogbol resectie - speekselklierresectie (met uitzondering van de accessoire speekselklieren) - partiële of totale glossectomie - thyroïdectomie - parathyroïdectomie - pharyngectomie - incisionele borstbiopsie - borsttumorectomie - partiële cystectomie (met uitzondering van de endoscopische blaasresectie) - prostaatadenomectomie - epididymectomie - orchidectomie	Examen histologique par inclusion et coupe, quel que soit le nombre de coupes et quel que soit le nombre d'organes examinés, en ce compris l'examen macroscopique éventuel des pièces opératoires suivantes : - exérèse de ganglion lymphatique - évidement ganglionnaire axillaire unilatéral - évidement ganglionnaire inguinal unilatéral - biopsie pulmonaire chirurgicale pour indication non-oncologique - thymectomie partielle ou totale - résection de tumeur sous-fasciale - hépatectomie partielle - cholécystectomie - splénectomie - tumorectomie mésentérique - tumorectomie rétropéritonéale - résection du globe oculaire - résection d'une glande salivaire (à l'exception des glandes salivaires accessoires) - glossectomie partielle ou totale - thyroïdectomie - parathyroïdectomie - pharyngectomie - biopsie incisionnelle du sein - tumorectomie du sein - cystectomie partielle (à l'exception de la résection vésicale endoscopique) - adénomectomie prostatique - épидидymectomie - orchidectomie	



Nomenclature code	Description NL	Description FR	Years selected
	- partiële penisamputatie - diepe hals tumorectomie - partiële nefrectomie - adnexectomie - ovariectomie - salpingectomie - partiële vulvectomie - baarmoederhals conisatie of -resectie - bijnier resectie - zenuwbiopsie - spierbiopsie - hersen-, ruggenmerg- of hypofysetumor resectie - bottumor resectie - tonsillectomie (> 18 jaar) - adenoïdectomie (> 18 jaar)	- amputation partielle du pénis - tumorectomie profonde du cou - néphrectomie partielle - annexectomie - ovariectomie - salpingectomie - vulvectomie partielle - conisation ou résection du col de l'utérus - résection de la glande surrénale - biopsie nerveuse - biopsie musculaire - résection d'une tumeur du cerveau, de la moelle épinière ou de l'hypophyse - résection de tumeur osseuse - amygdalectomie (> 18 ans) - adénoïdectomie (> 18 ans)	
588011 - 588022	Histologisch onderzoek door inclusie en coupe, ongeacht het aantal coupes en ongeacht het aantal onderzochte organen, en met inbegrip van het eventueel macroscopisch onderzoek, van afnames die niet overeenkomen met de verstrekkingen 588232-588243, 588254-588265, 588276-588280, 588291-588302 of 587112-587123	Examen histologique par inclusion et coupe, quel que soit le nombre de coupes et quel que soit le nombre d'organes examinés, en ce compris l'examen macroscopique éventuel, des prélèvements ne correspondant pas aux prestations 588232-588243, 588254-588265, 588276-588280, 588291-588302 ou 587112-587123	
588291 - 588302	Histologisch onderzoek, door inclusie en coupe, ongeacht het aantal coupes en ongeacht het aantal onderzochte organen, en met inbegrip van het eventueel macroscopisch onderzoek, van volgende operatiestukken: - partiële mastectomie met okselklier(en) - totale mastectomie met of zonder okselklier(en) - partiële of totale pneumectomie voor niet-oncologische indicatie - partiële of totale slokdarmresectie voor niet-oncologische indicatie - bilaterale liesklieruitruiming - lymfeklier uitruiming van twee of meerdere groepen halsklieren	Examen histologique par inclusion et coupe, quel que soit le nombre de coupes et quel que soit le nombre d'organes examinés, en ce compris l'examen macroscopique éventuel des pièces opératoires suivantes : - mastectomie partielle avec ganglion(s) axillaire(s) - mastectomie totale avec ou sans ganglion(s) axillaire(s) - pneumectomie partielle ou totale pour indication non-oncologique - résection partielle ou totale de l'oesophage pour indication non-oncologique - évidement ganglionnaire inguinal bilatéral	



Nomenclature code	Description NL	Description FR	Years selected
	- tumorectomie van de mondbodem of het verhemelte - maxillectomie - partiële of totale gastrectomie voor niet-oncologische indicatie - dunne darm resectie - partiële of totale colectomie - pancreatectomie voor niet-oncologische indicatie - hysterectomie voor niet-oncologische indicatie - abdominoperineale resectie voor niet-oncologische indicatie - totale cystectomie voor niet-oncologische indicatie - totale penisamputatie - totale nefrectomie - hartresectie - hart long blok - totale hepatectomie - totale pelvectomie - totale vulvectomie - foetus van 14 tot en met 24 weken	- évidement de deux ou plusieurs groupes de ganglions du cou - tumorectomie du plancher buccal ou du palais - maxillectomie - gastrectomie partielle ou totale pour indication non-oncologique - résection de l'intestin grêle - colectomie partielle ou totale - pancréatectomie pour indication non-oncologique - hystérectomie pour indication non-oncologique - résection abdominopérinéale pour indication non-oncologique - cystectomie totale pour indication non-oncologique - amputation totale du pénis - néphrectomie totale - résection cardiaque - bloc cœur poumon(s) - hépatectomie totale - pelvectomie totale - vulvectomie totale - foetus de 14 à 24 semaines y compris	
588033 - 588044	Peroperatoir pathologisch-anatomisch extempore onderzoek, ongeacht het aantal afnames, volgens de vriesmethode of depmethode en ongeacht het aantal verrichte controle-onderzoeken na inclusie en coupe	Examen peropératoire extemporané quel que soit le nombre de prélèvements par la technique de congélation ou d'apposition sur lame quel que soit le nombre de contrôles effectués après inclusion et coupe	
588394 - 588405	Cytologisch onderzoek naar neoplastische cellen op urine of sputum ongeacht het aantal preparaten, per afname	Recherche cytologique de cellules néoplasiques dans l'urine ou l'expectoration, quel qu'en soit le nombre de lames, par prélèvement	
588416 - 588420	Cytologisch onderzoek naar neoplastische cellen op afnames niet gespecificeerd in de verstrekkingen 589853-589864 en 588394-588405, ongeacht het aantal preparaten, per afname	Recherche cytologique de cellules néoplasiques sur des prélèvements non précisés dans les prestations 589853-589864 et 588394-588405, quel que soit le nombre de lames, par prélèvement	



2. INDICATIONS FOR IHC TESTING

Table 4 – Most used stained according to the body sites, origin of the prelevement (Non extrapolated numbers).

Stain	Total number (% of the overall stains)	Body sites											
HP	1392 (14,6%)	0							1			1391	
Ki67	783 (8,2%)	20	127	1	7	9	3		8	31	138	211	228
Pan CK	409 (4,5%)	0	32	11	21	27	3	3	19	23	144	9	117
p16	384 (4%)	0	88		6		1		1	32	12	243	1
ER	352 (3,7%)	0	1				4		3	32	3	2	307
PR	322 (3,4%)	0	1				4		2	25	1	3	286
P53	314 (3,3%)	16	31	3	8	1	1		1	46	190	15	2
P63	312 (3,3%)	11	11	66	8	7	2		3	6	11	9	178
CD3	290 (3%)	0	10		9	1	1	2	36	9	221		1
Her2	289 (3%)	0	3		1		5		2		18		260
Melan A	260 (2,7%)	3	240		2	1	4	1	4		2		3
Ck7	225 (2,4%)	17	10	5	7	50	40	1	11	12	33	15	24
E-cadherine	138 (1,4%)	0					1		1		1		135
CMV	129 (1,4%)	0				3				2	123	1	
CK20	117 (1,2%)	21	7	4	1	11	18		9	5	36	1	4
TTF1	111 (1,2%)	1	1	2	7	76	9		4		5	1	5
HMB45	108 (1,1%)	2	101		1		1		1		1		1
CDX2	109 (1,1%)	0		1	2	3	14		3	2	84		
MSI	103 (1,1%)	1		1	1	1	7			12	80		
HPV	103 (1,1%)	0	19		1					2	10	71	
ck 5/6	122 (1%)	2	8	16	4	14	2		1	2	2	2	69
CD20	101 (1%)	1	9		7	2	1	1	40	9	30		1



P504S	90 (0,9%)	10		79					1				
SOX10	89 (0,9%)	0	81				2		1		2		3
P40	86 (0,9%)	1	10		8	48	2		2	3	5	1	6
CK 8/18	115 (0,9%)	2	2		4	1	1		1	1	78		25
s100	83 (0,9%)	4	40	3	4	3			6		17	1	5
Ck34βE12	79 (0,8%)	4	3	65	2				1	2			2
PD-L1	77 (0,8%)	4	2	1	1	58	1		3				7
BER-EP4	75 (0,8%)	1	43		5	4	2		4	1	6	5	4
CD68	81 (0,7%)	3	17		9		7	2	7	2	21		13
Others	2302 (24,7%)	107	375	46	140	240	51	102	232	188	565	62	194



3. SURVEY TO ALL BELGIAN LABORATORIES

3.1. IHC stains questionnaire (nomenclature codes 588070-588081)

1. How many immunohistochemistry stains has your lab performed in 2019 and 2022 (reimbursed and non-reimbursed)?
2. What % of these fell within the current reimbursement system, for the years 2019 and 2022 ?
3. Please give the main reasons why some IHC stains were not reimbursed.
4. Which are the top 5 most requested immunohistochemical stains in your laboratory? (provide these data for the year 2022).

For each of these stains, please mention the main reason why they were requested/performed? Try to distinguish between oncological and non-oncological / functional indication(s), and limit yourself to the 3 most important indications where possible and relevant.

Remark: If several clones (e.g. for cytokeratins) are used interchangeably for a similar indication, please try to mention the common name or the name of the cocktail, e.g. broad spectrum cytokeratins, when possible.

5. Could you specify on what basis decisions on whether to carry out the previously mentioned stains are made for each of the indications mentioned in question 2.? (eg. Protocols, guidelines, pathologist's decision...). If you have any documents or references that could be informative to our research please attach them here. If decisions are taken by the pathologist, please describe the flow of decisions for each indication.

6. Should you like to raise any points that you believe could be informative for this research please do so. If you have any documents or references you would like to share with the KCE team, please attach/list them here.

3.2. EM examinations questionnaire

1. Which are the top 3 most common biopsy sites (organs) for Electron microscopy? If possible, provide this data for the year 2022.

For each of the previously mentioned biopsy sites, please mention the indications or reason why they were requested/performed?

2. Could you specify on what basis decisions on whether to carry out the previously mentioned EM examinations are made for each of the indications mentioned in question 1.? (eg. Protocols, guidelines, pathologist decision...). If you have any documents or references that could be informative to our research please attach them here. If decisions are taken by the pathologist, please describe the flow of decisions for each indication.
3. Are there any alternative tests to EM that you use in the previously mentioned indications? If so, which ones and under what circumstances, please describe them.
4. Should you like to raise any points that you believe could be informative for this research please do so. If you have any documents or references you would like to share with the KCE team, please attach/list them here.



3.3. Other IHC stains cited by laboratories

Table 5 – Detail of the other IHC stains cited by laboratories as the 5 most frequent

IHC stain	1st most frequent	2nd most frequent	3th most frequent	4th most frequent	5th most frequent	Total
P40			1		1	2
P504S				2		2
CK7				1	1	2
PR				2		2
CK8/18	1					1
MSI		1				1
CD8		1				1
CD138				1		1
keratine 34betaE12				1		1
CK17				1		1
CKCO				1		1
E-cadherine				1		1
SOX-10				1		1
NUM-1					1	1
CDX2					1	1
CK5/6					1	1
Prame					1	1
OR					1	1
CMV					1	1



4. REVIEWS OF THE LITERATURE

4.1. Search strategies

H. Pylori searches

4.1.1. *Cochrane*

Date 03/10/2023

Database Cochrane

Search strategy

1	[mh "helicobacter pylori"[mj]]	799
2	[mh "Helicobacter Infections"[mj]]	1972
3	#1 or #2	2055
4	helicobacter:ti,kw	5523
5	"h pylori":ti,kw	720
6	#4 or #5	5948
7	#3 or #6	5948
8	#7 with Cochrane Library publication date Between Jan 2010 and Dec 2023, in Cochrane Reviews	10



4.1.2. Embase

Date 2 /10/2023

Database Embase

Search strategy

1	'helicobacter pylori'/exp/mj	30002
2	'helicobacter infection'/exp/mj	21920
3	helicobacter:ti,kw	49682
4	'h pylori':ti,kw	7106
5	#1 OR #2 OR #3 OR #4	56918
6	'clinical pathway'/exp	9915
7	'clinical protocol'/exp	122075
8	'consensus'/exp	101354
9	'consensus development'/exp	28038
10	'clinical pathway'/de	9915
11	'guideline'/de	142
12	'practice guideline'/exp	717428
13	'health care planning'/de	113878
14	#6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13	905717



15	guideline:ti	27171
16	'position statement*':ti,ab,kw OR 'policy statement*':ti,ab,kw OR 'practice parameter*':ti,ab,kw OR 'best practice*':ti,ab,kw	67841
17	standards:ti,kw OR guideline:ti,kw OR guidelines:ti,kw	188875
18	((practice OR treatment* OR clinical) NEAR/5 guideline*):ab	145267
19	cpg:ti OR cpgs:ti	7786
20	consensus*:ti,kw	44424
21	((critical OR clinical OR practice) NEAR/2 (path OR paths OR pathway OR pathways OR protocol*)):ti,ab,kw	41731
22	recommenda*:ti,kw	68887
23	(care NEAR/2 (standard OR path OR paths OR pathway OR pathways OR map OR maps OR plan OR plans)):ti,ab,kw	152989
24	(algorithm* NEAR/2 (screening OR examination OR test OR tested OR testing OR assessment* OR diagnosis OR diagnoses OR diagnosed OR diagnosing)):ti,ab,kw	14668
25	(algorithm* NEAR/2 (pharmacotherap* OR chemotherap* OR chemotreatment* OR therap* OR treatment* OR intervention*)):ti,ab,kw	19769
26	#15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25	670639
27	#14 OR #26	1340669
28	#5 AND #27	1968



29	#28 AND [2010-2023]/py	1155
30	#29 NOT [medline]/lim	573
31	#30 NOT ('conference abstract'/it OR 'conference paper'/it OR 'conference review'/it)	230
32	#5 AND ('meta-analysis'/exp OR 'meta-analysis' OR 'systematic review'/exp OR 'systematic review')	2043
33	#32 AND [2010-2023]/py	1598
34	#33 NOT ('conference abstract'/it OR 'conference paper'/it OR 'conference review'/it)	1231
35	#34 NOT [medline]/lim	311

4.1.3. Medline

Date 19/9/ 2023

Database Ovid MEDLINE(R) and Epub Ahead of Print, In-Process, In-Data-Review & Other Non-Indexed Citations, Daily and Versions <1946 to September 19, 2023>

Search strategy

1	*helicobacter pylori/	31173
2	*Helicobacter Infections/	27921
3	helicobacter.ti,kf.	36339
4	h pylori.ti,kf.	3092



5	1 or 2 or 3 or 4	41622
6	exp clinical pathway/	7856
7	exp clinical protocol/	190778
8	exp consensus/	21293
9	exp consensus development conference/	12667
10	exp consensus development conferences as topic/	3000
11	critical pathways/	7856
12	exp guideline/	37929
13	guidelines as topic/	42085
14	exp practice guideline/	30658
15	practice guidelines as topic/	127627
16	health planning guidelines/	4165
17	(guideline or practice guideline or consensus development conference or consensus development conference, NIH).pt.	47835
18	(position statement* or policy statement* or practice parameter* or best practice*).ti,ab,kf,kw.	47267
19	(standards or guideline or guidelines).ti,kf,kw.	137528
20	((practice or treatment* or clinical) adj guideline*).ab.	53862
21	(CPG or CPGs).ti.	6476



22	consensus*.ti,kf,kw.	35653
23	consensus*.ab. /freq=2	34986
24	((critical or clinical or practice) adj2 (path or paths or pathway or pathways or protocol*)).ti,ab,kf,kw.	27135
25	recommendat*.ti,kf,kw.	54492
26	(care adj2 (standard or path or paths or pathway or pathways or map or maps or plan or plans)).ti,ab,kf,kw.	85703
27	(algorithm* adj2 (screening or examination or test or tested or testing or assessment* or diagnosis or diagnoses or diagnosed or diagnosing)).ti,ab,kf,kw.	10559
28	(algorithm* adj2 (pharmacotherap* or chemotherap* or chemotreatment* or therap* or treatment* or intervention*)).ti,ab,kf,kw.	13219
29	or/6-28	754767
30	5 and 29	886
31	limit 30 to yr="2010-2023"	466
32	remove duplicates from 31	465
33	((systematic review or systematic literature review or systematic scoping review or systematic narrative review or systematic qualitative review or systematic evidence review or systematic quantitative review or systematic meta-review or systematic critical review or systematic mixed studies review or systematic mapping review or systematic cochrane review or "systematic search and review" or systematic integrative review).ti. not	279737



	comment.pt. not (protocol or protocols).ti. not medline.st.) or (Cochrane Database Syst Rev.ja. and review.pt.) or systematic review.pt.	
34	meta-analys*.ti.	184909
35	meta-analysis.pt.	186784
36	exp Technology Assessment, Biomedical/	12192
37	health technology assessment.ti,kf.	2823
38	HtA.ti,kf.	862
39	33 or 34 or 35 or 36 or 37 or 38	403534
40	30 and 39	35
41	40 not 32	11

Coeliac disease searches

Database: *Ovid MEDLINE(R) ALL* <1946 to December 20, 2023>

Search Strategy:

-
- 1 exp Humans/ or immunohistochemistry.mp. (21661036)
 - 2 immunohistochemistry.mp. or exp Immunohistochemistry/ (760069)
 - 3 immunohistochemistry.ab,ti,kf. (232145)
 - 4 IHC.ab,ti,kf. (29893)
 - 5 Immunohistocytochem*.ab,ti,kf. (86)



- 6 Immuno-histochem*.ab,ti,kf. (2183)
- 7 Immunohisto-chem*.ab,ti,kf. (287)
- 8 Immunocytochemistry.ab,ti,kf. (37323)
- 9 Immunogold-Silver.ab,ti,kf. (468)
- 10 Immunolabeling.ab,ti,kf. (7282)
- 11 Immunogold.ab,ti,kf. (9783)
- 12 Fluorescent Antibod*.ab,ti,kf. (9178)
- 13 Fluorescent Antinuclear Antibod*.ab,ti,kf. (86)
- 14 ((Coon's or Coon or Coons) adj2 (Technique? or Technic?)).ab,ti,kf. (38)
- 15 Fluorescent Protein Tracing?.ab,ti,kf. (9)
- 16 Immunofluorescence.ab,ti,kf. (141689)
- 17 immuno-fluorescence.ab,ti,kf. (753)
- 18 immunofluorometric Assay?.ab,ti,kf. (739)
- 19 17 or 18 (1492)
- 20 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 (885487)
- 21 1 or 20 (22026304)
- 22 ((systematic review or systematic literature review or systematic scoping review or systematic narrative review or systematic qualitative review or systematic evidence review or systematic quantitative review or systematic meta-review or systematic critical review or systematic mixed studies review or systematic mapping review or systematic cochrane review or "systematic search and review" or systematic integrative review).ti. not comment.pt. not (protocol or protocols).ti. not medline.st.) or (Cochrane Database Syst Rev.ja. and review.pt.) or systematic review.pt. (292560)
- 23 meta-analys*.ti. (191542)
- 24 meta-analysis.pt. (191829)
- 25 exp Technology Assessment, Biomedical/ (12243)
- 26 limit 25 to humans (9251)
- 27 health technology assessment.ti,kf. (2903)



- 28 HtA.ti,kf. (886)
- 29 22 or 23 or 24 or 26 or 27 or 28 (415239)
- 30 limit 29 to yr=2000-2023 (405422)
- 31 exp clinical pathway/ (7909)
- 32 exp clinical protocol/ (191862)
- 33 exp consensus/ (21816)
- 34 exp consensus development conference/ (12678)
- 35 exp consensus development conferences as topic/ (3000)
- 36 critical pathways/ (7909)
- 37 exp guideline/ (38031)
- 38 guidelines as topic/ (42097)
- 39 exp practice guideline/ (30926)
- 40 practice guidelines as topic/ (127758)
- 41 health planning guidelines/ (4165)
- 42 (guideline or practice guideline or consensus development conference or consensus development conference, NIH).pt. (47946)
- 43 (position statement* or policy statement* or practice parameter* or best practice*).ti,ab,kf,kw. (48538)
- 44 (standards or guideline or guidelines).ti,kf,kw. (139718)
- 45 ((practice or treatment* or clinical) adj guideline*).ab. (55087)
- 46 (CPG or CPGs).ti. (6526)
- 47 consensus*.ti,kf,kw. (36439)
- 48 consensus*.ab. /freq=2 (35851)
- 49 ((critical or clinical or practice) adj2 (path or paths or pathway or pathways or protocol*)).ti,ab,kf,kw. (27751)
- 50 recommendat*.ti,kf,kw. (55571)
- 51 (care adj2 (standard or path or paths or pathway or pathways or map or maps or plan or plans)).ti,ab,kf,kw. (87992)



- 52 (algorithm* adj2 (screening or examination or test or tested or testing or assessment* or diagnosis or diagnoses or diagnosed or diagnosing)).ti,ab,kf,kw. (10774)
- 53 (algorithm* adj2 (pharmacotherap* or chemotherap* or chemotreatment* or therap* or treatment* or intervention*)).ti,ab,kf,kw. (13457)
- 54 or/31-53 (765141)
- 55 exp Celiac Disease/ or celiac.mp. (37592)
- 56 30 or 54 (1146580)
- 57 21 and 55 and 56 (1091)
- 58 limit 57 to yr=2000-2023 (1025)
- 59 limit 57 to yr=2013-2023 (722)

Embase

No.	Query Results	Results	Date
#24.	#23 AND ('practice guideline'/de OR 'systematic review'/de)	20	21 Dec 2023
#23.	#20 AND (2013:py OR 2014:py OR 2015:py OR 2016:py OR 2017:py OR 2018:py OR 2019:py OR 2020:py OR 2021:py OR 2022:py OR 2023:py) AND [embase]/lim AND [humans]/lim	880	21 Dec 2023
#22.	#20 AND (2013:py OR 2014:py OR 2015:py OR 2016:py OR 2017:py OR 2018:py OR 2019:py OR 2020:py OR 2021:py OR 2022:py OR 2023:py) AND [embase]/lim	970	21 Dec 2023
#21.	#20 AND (2013:py OR 2014:py OR 2015:py OR 2016:py OR 2017:py OR 2018:py OR 2019:py OR 2020:py OR 2021:py OR 2022:py OR 2023:py)	995	21 Dec 2023



#20. #16 AND #19	2,145	21 Dec 2023
#19. #17 OR #18	56,371	21 Dec 2023
#18. celiac:ab,ti,kw	37,613	21 Dec 2023
#17. 'celiac disease'	42,885	21 Dec 2023
#16. #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR	1,062,844	21 Dec 2023
#9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15		
#15. ((coon OR coons) NEAR/2 (technique\$ OR	39	21 Dec 2023
technic\$)):ab,ti,kw		
#14. immunofluorescence:ab,ti,kw	193,966	21 Dec 2023
#13. 'fluorescent protein tracing\$:ab,ti,kw	17	21 Dec 2023
#12. 'fluorescent antinuclear antibod*:ab,ti,kw	95	21 Dec 2023
#11. 'fluorescent antibod*:ab,ti,kw	9,335	21 Dec 2023
#10. immunogold:ab,ti,kw	10,998	21 Dec 2023
#9. immunolabeling:ab,ti,kw	8,924	21 Dec 2023
#8. 'immunogold-silver':ab,ti,kw	495	21 Dec 2023
#7. immunocytochemistry:ab,ti,kw	53,022	21 Dec 2023
#6. 'immunohisto chem*:ab,ti,kw	1,659	21 Dec 2023
#5. 'immuno histochem*:ab,ti,kw	4,301	21 Dec 2023
#4. immunohistocytochem*:ab,ti,kw	114	21 Dec 2023
#3. ihc:ab,ti,kw	68,323	21 Dec 2023
#2. immunohistochemistry:ab,ti,kw	366,726	21 Dec 2023
#1. ('immunohistochemistry'/exp OR	787,143	21 Dec 2023
'immunohistochemistry') AND [embase]/lim		

.....

**Search Name: Cochrane_CeliacIHC**

Date Run: 21/12/2023 04:35:04

ID	Search Hits
#1	MeSH descriptor: [Celiac Disease] explode all trees 514
#2	IHC:ab,ti,kw 2363
#3	Immunohistochem*:ab,ti,kw 0
#4	Immuno-histochem*:ab,ti,kw 62
#5	Immunohisto-chem*:ab,ti,kw 6
#6	Immunocytochemistry:ab,ti,kw 190
#7	"Immunogold-Silver":ab,ti,kw 1
#8	Immunolabeling:ab,ti,kw 17
#9	Immunogold:ab,ti,kw 9
#10	(Fluorescent NEAR/1 Antibod*):ab,ti,kw 332
#11	((Coon's or Coon or Coons) NEAR/2 (technique? or technic?):ab,ti,kw 0
#12	Fluorescent Protein Tracing?:ab,ti,kw 1
#13	Immunofluorescence:ab,ti,kw 1111
#14	immuno-fluorescence:ab,ti,kw 7
#15	#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 4443
#16	celiac:ab,ti,kw 1527
#17	#1 OR #16 1527
#18	#15 AND #17 with Cochrane Library publication date Between Jan 2013 and Dec 2023 362
#19	MeSH descriptor: [Celiac Disease] explode all trees 514
#20	IHC:ab,ti,kw 2363



#21 Immunohistochem*:ab,ti,kw 0
#22 Immuno-histochem*:ab,ti,kw 62
#23 Immunohisto-chem*:ab,ti,kw 6
#24 Immunocytochemistry:ab,ti,kw 190
#25 "Immunogold-Silver":ab,ti,kw 1
#26 Immunolabeling:ab,ti,kw 17
#27 Immunogold:ab,ti,kw 9
#28 (Fluorescent NEAR/1 Antibod*):ab,ti,kw 332
#29 ((Coon's or Coon or Coons) NEAR/2 (technique? or technic?)):ab,ti,kw 0
#30 Fluorescent Protein Tracing?:ab,ti,kw 1
#31 Immunofluorescence:ab,ti,kw 1111
#32 immuno-fluorescence:ab,ti,kw 7
#33 #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28 OR #29 OR #30 OR #31 OR #32 4443
#34 celiac:ab,ti,kw 1527
#35 #19 OR #34 1527
#36 #33 AND #35 with Cochrane Library publication date Between Jan 2013 and Dec 2023 362

Electron microscopy searches

Database: Ovid MEDLINE(R) and Epub Ahead of Print, In-Process, In-Data-Review & Other Non-Indexed Citations, Daily and Versions <1946 to October 09, 2023>

Search Strategy: Dyskinesia

-
- 1 exp microscopy, electron/ (371271)
 - 2 (electron? adj2 microscop*).ab,ti,kf. (391655)



- 3 ImmunoElectron Microscop*.ab,ti,kf. (9954)
- 4 Volume EM.ab,ti,kf. (67)
- 5 Serial Block-Face SEM?.ab,ti,kf. (39)
- 6 Serial Sectioning TEM?.ab,ti,kf. (2)
- 7 ssTEM.ab,ti,kf. (34)
- 8 FIB-SEM.ab,ti,kf. (765)
- 9 Focused Ion Beam SEM.ab,ti,kf. (48)
- 10 SBF-SEM.ab,ti,kf. (146)
- 11 Electron Cryomicroscop*.ab,ti,kf. (786)
- 12 Cryo-electron Microscop*.ab,ti,kf. (6997)
- 13 Electron Probe Microanalyses.ab,ti,kf. (24)
- 14 X-Ray Microanalysis.ab,ti,kf. (3332)
- 15 Electron Probe?.ab,ti,kf. (2350)
- 16 (STEM adj5 microscop*).ab,ti,kf. (2797)
- 17 EFTEM.ab,ti,kf. (221)
- 18 Electron Spectroscopic Imaging.ab,ti,kf. (263)
- 19 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 (403668)
- 20 1 or 19 (602954)
- 21 ((systematic review or systematic literature review or systematic scoping review or systematic narrative review or systematic qualitative review or systematic evidence review or systematic quantitative review or systematic meta-review or systematic critical review or systematic mixed studies review or systematic mapping review or systematic cochrane review or "systematic search and review" or systematic integrative review).ti. not comment.pt. not (protocol or protocols).ti. not medline.st.) or (Cochrane Database Syst Rev.ja. and review.pt.) or systematic review.pt. (283720)
- 22 meta-analys*.ti. (186442)
- 23 meta-analysis.pt. (187712)
- 24 exp Technology Assessment, Biomedical/ (12207)



- 25 health technology assessment.ti,kf. (2845)
- 26 HtA.ti,kf. (866)
- 27 21 or 22 or 23 or 24 or 25 or 26 (407521)
- 28 20 and 27 (109)
- 29 exp clinical pathway/ (7870)
- 30 exp clinical protocol/ (190976)
- 31 exp consensus/ (21411)
- 32 exp consensus development conference/ (12671)
- 33 exp consensus development conferences as topic/ (3000)
- 34 critical pathways/ (7870)
- 35 exp guideline/ (37962)
- 36 guidelines as topic/ (42086)
- 37 exp practice guideline/ (30689)
- 38 practice guidelines as topic/ (127658)
- 39 health planning guidelines/ (4165)
- 40 (guideline or practice guideline or consensus development conference or consensus development conference, NIH).pt. (47870)
- 41 (position statement* or policy statement* or practice parameter* or best practice*).ti,ab,kf,kw. (47564)
- 42 (standards or guideline or guidelines).ti,kf,kw. (138007)
- 43 ((practice or treatment* or clinical) adj guideline*).ab. (54154)
- 44 (CPG or CPGs).ti. (6485)
- 45 consensus*.ti,kf,kw. (35826)
- 46 consensus*.ab. /freq=2 (35187)
- 47 ((critical or clinical or practice) adj2 (path or paths or pathway or pathways or protocol*)).ti,ab,kf,kw. (27293)
- 48 recommendat*.ti,kf,kw. (54721)



- 49 (care adj2 (standard or path or paths or pathway or pathways or map or maps or plan or plans)).ti,ab,kf,kw. (86214)
- 50 (algorithm* adj2 (screening or examination or test or tested or testing or assessment* or diagnosis or diagnoses or diagnosed or diagnosing)).ti,ab,kf,kw. (10616)
- 51 (algorithm* adj2 (pharmacotherap* or chemotherap* or chemotreatment* or therap* or treatment* or intervention*)).ti,ab,kf,kw. (13276)
- 52 or/29-51 (757065)
- 53 20 and 52 (1023)
- 54 limit 20 to yr="2010-2023" (236930)
- 55 exp Ciliary Motility Disorders/ (2666)
- 56 ciliary motility disorder?.ab,ti,kf. (24)
- 57 immotile cilia syndrome.ab,ti,kf. (269)
- 58 ciliary d#skinesia?.ab,ti,kf. (1972)
- 59 Motile Ciliary Disorder?.ab,ti,kf. (3)
- 60 kartagener syndrome.ab,ti,kf. (373)
- 61 kartagener triad.ab,ti,kf. (140)
- 62 kartagener's syndrome.ab,ti,kf. (560)
- 63 kartagener's triad.ab,ti,kf. (31)
- 64 kartageners syndrome.ab,ti,kf. (560)
- 65 kartageners triad.ab,ti,kf. (31)
- 66 polynesian bronchiectas*.ab,ti,kf. (2)
- 67 ciliopathies.ti,kf. (476)
- 68 ciliopathy.ti,kf. (734)
- 69 56 or 57 or 58 or 59 or 60 or 61 or 62 or 63 or 64 or 65 or 66 or 67 or 68 (3946)
- 70 55 or 69 (4568)
- 71 28 and 70 (7)



72 53 and 70 (13)

73 54 and 70 (296)

74 73 not (animals/ not human/) (272)

Database: Ovid MEDLINE(R) and Epub Ahead of Print, In-Process, In-Data-Review & Other Non-Indexed Citations, Daily and Versions <1946 to October 09, 2023>

Search Strategy: Ehler Danlos

-
- 1 exp microscopy, electron/ (371271)
 - 2 (electron? adj2 microscop*).ab,ti,kf. (391655)
 - 3 ImmunoElectron Microscop*.ab,ti,kf. (9954)
 - 4 Volume EM.ab,ti,kf. (67)
 - 5 Serial Block-Face SEM?.ab,ti,kf. (39)
 - 6 Serial Sectioning TEM?.ab,ti,kf. (2)
 - 7 ssTEM.ab,ti,kf. (34)
 - 8 FIB-SEM.ab,ti,kf. (765)
 - 9 Focused Ion Beam SEM.ab,ti,kf. (48)
 - 10 SBF-SEM.ab,ti,kf. (146)
 - 11 Electron Cryomicroscop*.ab,ti,kf. (786)
 - 12 Cryo-electron Microscop*.ab,ti,kf. (6997)
 - 13 Electron Probe Microanalyses.ab,ti,kf. (24)
 - 14 X-Ray Microanalysis.ab,ti,kf. (3332)
 - 15 Electron Probe?.ab,ti,kf. (2350)
 - 16 (STEM adj5 microscop*).ab,ti,kf. (2797)
 - 17 EFTEM.ab,ti,kf. (221)



- 18 Electron Spectroscopic Imaging.ab,ti,kf. (263)
- 19 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 (403668)
- 20 1 or 19 (602954)
- 21 ((systematic review or systematic literature review or systematic scoping review or systematic narrative review or systematic qualitative review or systematic evidence review or systematic quantitative review or systematic meta-review or systematic critical review or systematic mixed studies review or systematic mapping review or systematic cochrane review or "systematic search and review" or systematic integrative review).ti. not comment.pt. not (protocol or protocols).ti. not medline.st.) or (Cochrane Database Syst Rev.ja. and review.pt.) or systematic review.pt. (283720)
- 22 meta-analys*.ti. (186442)
- 23 meta-analysis.pt. (187712)
- 24 exp Technology Assessment, Biomedical/ (12207)
- 25 health technology assessment.ti,kf. (2845)
- 26 HtA.ti,kf. (866)
- 27 21 or 22 or 23 or 24 or 25 or 26 (407521)
- 28 20 and 27 (109)
- 29 exp clinical pathway/ (7870)
- 30 exp clinical protocol/ (190976)
- 31 exp consensus/ (21411)
- 32 exp consensus development conference/ (12671)
- 33 exp consensus development conferences as topic/ (3000)
- 34 critical pathways/ (7870)
- 35 exp guideline/ (37962)
- 36 guidelines as topic/ (42086)
- 37 exp practice guideline/ (30689)
- 38 practice guidelines as topic/ (127658)
- 39 health planning guidelines/ (4165)



- 40 (guideline or practice guideline or consensus development conference or consensus development conference, NIH).pt. (47870)
- 41 (position statement* or policy statement* or practice parameter* or best practice*).ti,ab,kf,kw. (47564)
- 42 (standards or guideline or guidelines).ti,kf,kw. (138007)
- 43 ((practice or treatment* or clinical) adj guideline*).ab. (54154)
- 44 (CPG or CPGs).ti. (6485)
- 45 consensus*.ti,kf,kw. (35826)
- 46 consensus*.ab. /freq=2 (35187)
- 47 ((critical or clinical or practice) adj2 (path or paths or pathway or pathways or protocol*)).ti,ab,kf,kw. (27293)
- 48 recommendat*.ti,kf,kw. (54721)
- 49 (care adj2 (standard or path or paths or pathway or pathways or map or maps or plan or plans)).ti,ab,kf,kw. (86214)
- 50 (algorithm* adj2 (screening or examination or test or tested or testing or assessment* or diagnosis or diagnoses or diagnosed or diagnosing)).ti,ab,kf,kw. (10616)
- 51 (algorithm* adj2 (pharmacotherap* or chemotherap* or chemotreatment* or therap* or treatment* or intervention*)).ti,ab,kf,kw. (13276)
- 52 or/29-51 (757065)
- 53 20 and 52 (1023)
- 54 limit 20 to yr="2010-2023" (236930)
- 55 exp Ehlers-Danlos Syndrome/ (3746)
- 56 Cutis Elastica.ab,ti,kf. (2)
- 57 Ehlers Danlos.ab,ti,kf. (4372)
- 58 Cutis hyperelastica.ab,ti,kf. (22)
- 59 Classical EDS.ab,ti,kf. (55)
- 60 (EDS adj3 Type I?).ab,ti,kf. (214)
- 61 Hypermobility EDS.ab,ti,kf. (57)
- 62 Vascular EDS.ab,ti,kf. (87)



- 63 Kyphoscoliotic EDS.ab,ti,kf. (6)
- 64 Arthrochalasia EDS.ab,ti,kf. (4)
- 65 Dermatosparaxis EDS.ab,ti,kf. (4)
- 66 (EDS adj3 Type V?).ab,ti,kf. (38)
- 67 (EDS adj3 Type VI??).ab,ti,kf. (74)
- 68 56 or 57 or 58 or 59 or 60 or 61 or 62 or 63 or 64 or 65 or 66 or 67 (4395)
- 69 55 or 68 (5007)
- 70 28 and 69 (0)
- 71 53 and 69 (0)
- 72 54 and 69 (60)
- 73 72 not (animals/ not human/) (46)

Database: Ovid MEDLINE(R) and Epub Ahead of Print, In-Process, In-Data-Review & Other Non-Indexed Citations, Daily and Versions <1946 to October 09, 2023>

Search Strategy: Meningioma

-
- 1 exp microscopy, electron/ (371271)
 - 2 (electron? adj2 microscop*).ab,ti,kf. (391655)
 - 3 ImmunoElectron Microscop*.ab,ti,kf. (9954)
 - 4 Volume EM.ab,ti,kf. (67)
 - 5 Serial Block-Face SEM?.ab,ti,kf. (39)
 - 6 Serial Sectioning TEM?.ab,ti,kf. (2)
 - 7 ssTEM.ab,ti,kf. (34)
 - 8 FIB-SEM.ab,ti,kf. (765)
 - 9 Focused Ion Beam SEM.ab,ti,kf. (48)



- 10 SBF-SEM.ab,ti,kf. (146)
- 11 Electron Cryomicroscop*.ab,ti,kf. (786)
- 12 Cryo-electron Microscop*.ab,ti,kf. (6997)
- 13 Electron Probe Microanalyses.ab,ti,kf. (24)
- 14 X-Ray Microanalysis.ab,ti,kf. (3332)
- 15 Electron Probe?.ab,ti,kf. (2350)
- 16 (STEM adj5 microscop*).ab,ti,kf. (2797)
- 17 EFTEM.ab,ti,kf. (221)
- 18 Electron Spectroscopic Imaging.ab,ti,kf. (263)
- 19 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 (403668)
- 20 1 or 19 (602954)
- 21 ((systematic review or systematic literature review or systematic scoping review or systematic narrative review or systematic qualitative review or systematic evidence review or systematic quantitative review or systematic meta-review or systematic critical review or systematic mixed studies review or systematic mapping review or systematic cochrane review or "systematic search and review" or systematic integrative review).ti. not comment.pt. not (protocol or protocols).ti. not medline.st.) or (Cochrane Database Syst Rev.ja. and review.pt.) or systematic review.pt. (283720)
- 22 meta-analys*.ti. (186442)
- 23 meta-analysis.pt. (187712)
- 24 exp Technology Assessment, Biomedical/ (12207)
- 25 health technology assessment.ti,kf. (2845)
- 26 HtA.ti,kf. (866)
- 27 21 or 22 or 23 or 24 or 25 or 26 (407521)
- 28 20 and 27 (109)
- 29 exp clinical pathway/ (7870)
- 30 exp clinical protocol/ (190976)
- 31 exp consensus/ (21411)



- 32 exp consensus development conference/ (12671)
- 33 exp consensus development conferences as topic/ (3000)
- 34 critical pathways/ (7870)
- 35 exp guideline/ (37962)
- 36 guidelines as topic/ (42086)
- 37 exp practice guideline/ (30689)
- 38 practice guidelines as topic/ (127658)
- 39 health planning guidelines/ (4165)
- 40 (guideline or practice guideline or consensus development conference or consensus development conference, NIH).pt. (47870)
- 41 (position statement* or policy statement* or practice parameter* or best practice*).ti,ab,kf,kw. (47564)
- 42 (standards or guideline or guidelines).ti,kf,kw. (138007)
- 43 ((practice or treatment* or clinical) adj guideline*).ab. (54154)
- 44 (CPG or CPGs).ti. (6485)
- 45 consensus*.ti,kf,kw. (35826)
- 46 consensus*.ab. /freq=2 (35187)
- 47 ((critical or clinical or practice) adj2 (path or paths or pathway or pathways or protocol*)).ti,ab,kf,kw. (27293)
- 48 recommendat*.ti,kf,kw. (54721)
- 49 (care adj2 (standard or path or paths or pathway or pathways or map or maps or plan or plans)).ti,ab,kf,kw. (86214)
- 50 (algorithm* adj2 (screening or examination or test or tested or testing or assessment* or diagnosis or diagnoses or diagnosed or diagnosing)).ti,ab,kf,kw. (10616)
- 51 (algorithm* adj2 (pharmacotherap* or chemotherap* or chemotreatment* or therap* or treatment* or intervention*)).ti,ab,kf,kw. (13276)
- 52 or/29-51 (757065)
- 53 20 and 52 (1023)
- 54 limit 20 to yr="2010-2023" (236930)



- 55 exp Meningioma/ (21498)
- 56 meningioma?.ab,ti,kf. (24937)
- 57 Meningiomas#.ab,ti,kf. (94)
- 58 (meningeal adj5 (tumo?* or neoplasm* or cancer* or carcinoma*)).ab,ti,kf. (1586)
- 59 56 or 57 or 58 (26194)
- 60 55 or 59 (31049)
- 61 28 and 60 (0)
- 62 53 and 60 (0)
- 63 54 and 60 (45)
- 64 63 not (animals/ not human/) (41)

Database: Ovid MEDLINE(R) and Epub Ahead of Print, In-Process, In-Data-Review & Other Non-Indexed Citations, Daily and Versions <1946 to October 18, 2023>

Search Strategy:

-
- 1 exp microscopy, electron/ (371236)
 - 2 (electron? adj2 microscop*).ab,ti,kf. (392000)
 - 3 ImmunoElectron Microscop*.ab,ti,kf. (9958)
 - 4 Volume EM.ab,ti,kf. (66)
 - 5 Serial Block-Face SEM?.ab,ti,kf. (40)
 - 6 Serial Sectioning TEM?.ab,ti,kf. (2)
 - 7 ssTEM.ab,ti,kf. (34)
 - 8 FIB-SEM.ab,ti,kf. (765)
 - 9 Focused Ion Beam SEM.ab,ti,kf. (48)
 - 10 SBF-SEM.ab,ti,kf. (147)



- 11 Electron Cryomicroscop*.ab,ti,kf. (786)
- 12 Cryo-electron Microscop*.ab,ti,kf. (6985)
- 13 Electron Probe Microanalyses.ab,ti,kf. (24)
- 14 X-Ray Microanalysis.ab,ti,kf. (3331)
- 15 Electron Probe?.ab,ti,kf. (2352)
- 16 (STEM adj5 microscop*).ab,ti,kf. (2801)
- 17 EFTEM.ab,ti,kf. (221)
- 18 Electron Spectroscopic Imaging.ab,ti,kf. (263)
- 19 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 (404017)
- 20 1 or 19 (603294)
- 21 ((systematic review or systematic literature review or systematic scoping review or systematic narrative review or systematic qualitative review or systematic evidence review or systematic quantitative review or systematic meta-review or systematic critical review or systematic mixed studies review or systematic mapping review or systematic cochrane review or "systematic search and review" or systematic integrative review).ti. not comment.pt. not (protocol or protocols).ti. not medline.st.) or (Cochrane Database Syst Rev.ja. and review.pt.) or systematic review.pt. (284306)
- 22 meta-analys*.ti. (186910)
- 23 meta-analysis.pt. (187573)
- 24 exp Technology Assessment, Biomedical/ (12203)
- 25 health technology assessment.ti,kf. (2850)
- 26 HtA.ti,kf. (867)
- 27 21 or 22 or 23 or 24 or 25 or 26 (408214)
- 28 20 and 27 (110)
- 29 exp clinical pathway/ (7865)
- 30 exp clinical protocol/ (190939)
- 31 exp consensus/ (21382)
- 32 exp consensus development conference/ (12671)



- 33 exp consensus development conferences as topic/ (3000)
- 34 critical pathways/ (7865)
- 35 exp guideline/ (37987)
- 36 guidelines as topic/ (42090)
- 37 exp practice guideline/ (30715)
- 38 practice guidelines as topic/ (127659)
- 39 health planning guidelines/ (4165)
- 40 (guideline or practice guideline or consensus development conference or consensus development conference, NIH).pt. (47896)
- 41 (position statement* or policy statement* or practice parameter* or best practice*).ti,ab,kf,kw. (47643)
- 42 (standards or guideline or guidelines).ti,kf,kw. (138134)
- 43 ((practice or treatment* or clinical) adj guideline*).ab. (54220)
- 44 (CPG or CPGs).ti. (6486)
- 45 consensus*.ti,kf,kw. (35885)
- 46 consensus*.ab. /freq=2 (35225)
- 47 ((critical or clinical or practice) adj2 (path or paths or pathway or pathways or protocol*)).ti,ab,kf,kw. (27321)
- 48 recommendat*.ti,kf,kw. (54802)
- 49 (care adj2 (standard or path or paths or pathway or pathways or map or maps or plan or plans)).ti,ab,kf,kw. (86352)
- 50 (algorithm* adj2 (screening or examination or test or tested or testing or assessment* or diagnosis or diagnoses or diagnosed or diagnosing)).ti,ab,kf,kw. (10619)
- 51 (algorithm* adj2 (pharmacotherap* or chemotherap* or chemotreatment* or therap* or treatment* or intervention*)).ti,ab,kf,kw. (13285)
- 52 or/29-51 (757580)
- 53 20 and 52 (1022)
- 54 limit 20 to yr="2010-2023" (237249)
- 55 exp Mitochondrial Myopathies/ (5444)



- 56 (mitochondr* adj5 (myopath* or muscle disorder?)).ab,ti,kf. (2828)
- 57 (pleoconial adj3 myopath*).ab,ti,kf. (2)
- 58 (luft? adj3 disease).ab,ti,kf. (16)
- 59 (megaconial adj3 myopath*).ab,ti,kf. (10)
- 60 (Mitochondr* adj3 Encephalomyopath*).ab,ti,kf. (1644)
- 61 (MELAS adj2 Syndrome).ab,ti,kf. (630)
- 62 (MERRF adj2 Syndrome).ab,ti,kf. (160)
- 63 (fukuhara adj2 (disease or syndrome)).ab,ti,kf. (3)
- 64 (myoclon* adj3 epileps*).ab,ti,kf. (4583)
- 65 Kearns-Sayre Syndrome.ab,ti,kf. (791)
- 66 cpeo.ab,ti,kf. (390)
- 67 (graefe? adj2 disease).ab,ti,kf. (4)
- 68 ocular myopath*.ab,ti,kf. (225)
- 69 ocular muscular dystroph*.ab,ti,kf. (10)
- 70 progressive external ophthalmoplegia?.ab,ti,kf. (1165)
- 71 graefe fuchs.ab,ti,kf. (0)
- 72 (kearn? adj2 sayre).ab,ti,kf. (834)
- 73 (kearn? adj2 (syndrome or cytopath*)).ab,ti,kf. (847)
- 74 ophthalmoplegia plus syndrome.ab,ti,kf. (9)
- 75 oculocraniosomatic syndrome.ab,ti,kf. (4)
- 76 MELAS.ab,ti,kf. (2384)
- 77 MNGIE.ab,ti,kf. (274)
- 78 56 or 57 or 58 or 59 or 60 or 61 or 62 or 63 or 64 or 65 or 66 or 67 or 68 or 69 or 70 or 71 or 72 or 73 or 74 or 75 or 76 or 77 (11416)
- 79 55 or 78 (13131)



- 80 exp Myopathies, Structural, Congenital/ (1587)
- 81 (nemaline adj3 myopath*).ab,ti,kf. (930)
- 82 (nemaline adj3 disease).ab,ti,kf. (52)
- 83 (nemaline adj3 rod).ab,ti,kf. (112)
- 84 (rod body adj3 disease).ab,ti,kf. (1)
- 85 (rod adj3 myopath*).ab,ti,kf. (132)
- 86 (central core adj3 (disease? or myopath*)).ab,ti,kf. (484)
- 87 shy-magee.ab,ti,kf. (0)
- 88 (congenital adj3 myopath*).ab,ti,kf. (1695)
- 89 (centronuclear adj3 myopath*).ab,ti,kf. (537)
- 90 congenital fiber type disproportion?.ab,ti,kf. (149)
- 91 tubular aggregate myopathies.ab,ti,kf. (4)
- 92 (x linked adj3 myopath*).ab,ti,kf. (463)
- 93 xlmtm.ab,ti,kf. (123)
- 94 cftdm.ab,ti,kf. (3)
- 95 (myotubular adj3 myopath*).ab,ti,kf. (467)
- 96 81 or 82 or 83 or 84 or 85 or 86 or 87 or 88 or 89 or 90 or 91 or 92 or 93 or 94 or 95 (3448)
- 97 80 or 96 (3767)
- 98 Myositis, Inclusion Body/ (1351)
- 99 ('inclusion body' adj3 myositis).ab,ti,kf. (1931)
- 100 98 or 99 (2238)
- 101 Muscular Dystrophy, Duchenne/ (7180)
- 102 (muscular dystroph* adj3 duchenne).ab,ti,kf. (12426)
- 103 (muscular dystroph* adj3 becker).ab,ti,kf. (2108)



- 104 (muscular dystroph* adj3 beckers).ab,ti,kf. (163)
- 105 pseudohypertrophic muscular dystroph*.ab,ti,kf. (87)
- 106 102 or 103 or 104 or 105 (13133)
- 107 101 or 106 (14083)
- 108 79 or 97 or 100 or 107 (32751)
- 109 28 and 108 (1)
- 110 53 and 108 (1)
- 111 54 and 108 (314)
- 112 111 not (Animals/ not human/) (251)
- 113 remove duplicates from 112 (251)
- 114 remove duplicates from 112 (251)

Database: Ovid MEDLINE(R) and Epub Ahead of Print, In-Process, In-Data-Review & Other Non-Indexed Citations, Daily and Versions <1946 to October 18, 2023>

Search Strategy: Nephropathies

-
- 1 exp microscopy, electron/ (371236)
 - 2 (electron? adj2 microscop*).ab,ti,kf. (392000)
 - 3 ImmunoElectron Microscop*.ab,ti,kf. (9958)
 - 4 Volume EM.ab,ti,kf. (66)
 - 5 Serial Block-Face SEM?.ab,ti,kf. (40)
 - 6 Serial Sectioning TEM?.ab,ti,kf. (2)
 - 7 ssTEM.ab,ti,kf. (34)
 - 8 FIB-SEM.ab,ti,kf. (765)
 - 9 Focused Ion Beam SEM.ab,ti,kf. (48)



- 10 SBF-SEM.ab,ti,kf. (147)
- 11 Electron Cryomicroscop*.ab,ti,kf. (786)
- 12 Cryo-electron Microscop*.ab,ti,kf. (6985)
- 13 Electron Probe Microanalyses.ab,ti,kf. (24)
- 14 X-Ray Microanalysis.ab,ti,kf. (3331)
- 15 Electron Probe?.ab,ti,kf. (2352)
- 16 (STEM adj5 microscop*).ab,ti,kf. (2801)
- 17 EFTEM.ab,ti,kf. (221)
- 18 Electron Spectroscopic Imaging.ab,ti,kf. (263)
- 19 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 (404017)
- 20 1 or 19 (603294)
- 21 ((systematic review or systematic literature review or systematic scoping review or systematic narrative review or systematic qualitative review or systematic evidence review or systematic quantitative review or systematic meta-review or systematic critical review or systematic mixed studies review or systematic mapping review or systematic cochrane review or "systematic search and review" or systematic integrative review).ti. not comment.pt. not (protocol or protocols).ti. not medline.st.) or (Cochrane Database Syst Rev.ja. and review.pt.) or systematic review.pt. (284306)
- 22 meta-analys*.ti. (186910)
- 23 meta-analysis.pt. (187573)
- 24 exp Technology Assessment, Biomedical/ (12203)
- 25 health technology assessment.ti,kf. (2850)
- 26 HtA.ti,kf. (867)
- 27 21 or 22 or 23 or 24 or 25 or 26 (408214)
- 28 20 and 27 (110)
- 29 exp clinical pathway/ (7865)
- 30 exp clinical protocol/ (190939)
- 31 exp consensus/ (21382)



- 32 exp consensus development conference/ (12671)
- 33 exp consensus development conferences as topic/ (3000)
- 34 critical pathways/ (7865)
- 35 exp guideline/ (37987)
- 36 guidelines as topic/ (42090)
- 37 exp practice guideline/ (30715)
- 38 practice guidelines as topic/ (127659)
- 39 health planning guidelines/ (4165)
- 40 (guideline or practice guideline or consensus development conference or consensus development conference, NIH).pt. (47896)
- 41 (position statement* or policy statement* or practice parameter* or best practice*).ti,ab,kf,kw. (47643)
- 42 (standards or guideline or guidelines).ti,kf,kw. (138134)
- 43 ((practice or treatment* or clinical) adj guideline*).ab. (54220)
- 44 (CPG or CPGs).ti. (6486)
- 45 consensus*.ti,kf,kw. (35885)
- 46 consensus*.ab. /freq=2 (35225)
- 47 ((critical or clinical or practice) adj2 (path or paths or pathway or pathways or protocol*)).ti,ab,kf,kw. (27321)
- 48 recommendat*.ti,kf,kw. (54802)
- 49 (care adj2 (standard or path or paths or pathway or pathways or map or maps or plan or plans)).ti,ab,kf,kw. (86352)
- 50 (algorithm* adj2 (screening or examination or test or tested or testing or assessment* or diagnosis or diagnoses or diagnosed or diagnosing)).ti,ab,kf,kw. (10619)
- 51 (algorithm* adj2 (pharmacotherap* or chemotherap* or chemotreatment* or therap* or treatment* or intervention*)).ti,ab,kf,kw. (13285)
- 52 or/29-51 (757580)
- 53 20 and 52 (1022)
- 54 limit 20 to yr="2010-2023" (237249)



- 55 Kidney Transplantation/ (105648)
- 56 (kidney adj3 grafting).ab,ti,kf. (120)
- 57 (kidney adj3 transplantation?).ab,ti,kf. (37105)
- 58 (renal adj3 transplantation?).ab,ti,kf. (30419)
- 59 56 or 57 or 58 (62120)
- 60 55 or 59 (119741)
- 61 exp Glomerulonephritis/ (52316)
- 62 glomerulonephrit*.ab,ti,kf. (32004)
- 63 bright disease.ab,ti,kf. (12)
- 64 kidney scarring.ab,ti,kf. (75)
- 65 62 or 63 or 64 (32089)
- 66 61 or 65 (62160)
- 67 Nephrosis, Lipoid/ (2831)
- 68 lipoid nephros*.ab,ti,kf. (537)
- 69 ("minimal change" adj3 (disease? or glomerulonephrit* or glomerulopath* or nephropath* or nephrotic syndrome)).ab,ti,kf. (3632)
- 70 68 or 69 (4143)
- 71 67 or 70 (5015)
- 72 Glomerulosclerosis, Focal Segmental/ (5872)
- 73 focal glomerulosclerosis.ab,ti,kf. (582)
- 74 focal sclerosing glomerulonephrit*.ab,ti,kf. (41)
- 75 segmental glomerular hyalinosis.ab,ti,kf. (24)
- 76 segmental hyalinosis.ab,ti,kf. (59)
- 77 73 or 74 or 75 or 76 (698)
- 78 72 or 77 (6203)



- 79 Glomerulonephritis, Membranous/ (3959)
- 80 extramembranous glomerulopath*.ab,ti,kf. (13)
- 81 heyman nephritis.ab,ti,kf. (552)
- 82 membranous glomerulonephrit*.ab,ti,kf. (1662)
- 83 membranous glomerulonephropath*.ab,ti,kf. (119)
- 84 membranous glomerulopath*.ab,ti,kf. (393)
- 85 membranous nephropath*.ab,ti,kf. (4751)
- 86 80 or 81 or 82 or 83 or 84 or 85 (7009)
- 87 79 or 86 (7722)
- 88 Lupus Nephritis/ (7952)
- 89 lupus glomerulonephrit*.ab,ti,kf. (290)
- 90 lupus nephrit*.ab,ti,kf. (10341)
- 91 89 or 90 (10521)
- 92 88 or 91 (12286)
- 93 60 or 66 or 71 or 78 or 87 or 92 (184141)
- 94 28 and 93 (4)
- 95 53 and 93 (27)
- 96 54 and 93 (1284)
- 97 96 not (exp animals/ not human/) (1133)

Database: Ovid MEDLINE(R) and Epub Ahead of Print, In-Process, In-Data-Review & Other Non-Indexed Citations, Daily and Versions <1946 to October 10, 2023>

Search Strategy: Pyuitary

-
- 1 exp microscopy, electron/ (371275)



- 2 (electron? adj2 microscop*).ab,ti,kf. (391682)
- 3 ImmunoElectron Microscop*.ab,ti,kf. (9954)
- 4 Volume EM.ab,ti,kf. (67)
- 5 Serial Block-Face SEM?.ab,ti,kf. (39)
- 6 Serial Sectioning TEM?.ab,ti,kf. (2)
- 7 ssTEM.ab,ti,kf. (34)
- 8 FIB-SEM.ab,ti,kf. (765)
- 9 Focused Ion Beam SEM.ab,ti,kf. (48)
- 10 SBF-SEM.ab,ti,kf. (146)
- 11 Electron Cryomicroscop*.ab,ti,kf. (786)
- 12 Cryo-electron Microscop*.ab,ti,kf. (7001)
- 13 Electron Probe Microanalyses.ab,ti,kf. (24)
- 14 X-Ray Microanalysis.ab,ti,kf. (3332)
- 15 Electron Probe?.ab,ti,kf. (2350)
- 16 (STEM adj5 microscop*).ab,ti,kf. (2797)
- 17 EFTEM.ab,ti,kf. (221)
- 18 Electron Spectroscopic Imaging.ab,ti,kf. (263)
- 19 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 (403695)
- 20 1 or 19 (602981)
- 21 ((systematic review or systematic literature review or systematic scoping review or systematic narrative review or systematic qualitative review or systematic evidence review or systematic quantitative review or systematic meta-review or systematic critical review or systematic mixed studies review or systematic mapping review or systematic cochrane review or "systematic search and review" or systematic integrative review).ti. not comment.pt. not (protocol or protocols).ti. not medline.st.) or (Cochrane Database Syst Rev.ja. and review.pt.) or systematic review.pt. (283809)
- 22 meta-analys*.ti. (186500)
- 23 meta-analysis.pt. (187754)



- 24 exp Technology Assessment, Biomedical/ (12207)
- 25 health technology assessment.ti,kf. (2845)
- 26 HtA.ti,kf. (866)
- 27 21 or 22 or 23 or 24 or 25 or 26 (407628)
- 28 20 and 27 (110)
- 29 exp clinical pathway/ (7870)
- 30 exp clinical protocol/ (190981)
- 31 exp consensus/ (21412)
- 32 exp consensus development conference/ (12671)
- 33 exp consensus development conferences as topic/ (3000)
- 34 critical pathways/ (7870)
- 35 exp guideline/ (37965)
- 36 guidelines as topic/ (42086)
- 37 exp practice guideline/ (30692)
- 38 practice guidelines as topic/ (127658)
- 39 health planning guidelines/ (4165)
- 40 (guideline or practice guideline or consensus development conference or consensus development conference, NIH).pt. (47873)
- 41 (position statement* or policy statement* or practice parameter* or best practice*).ti,ab,kf,kw. (47571)
- 42 (standards or guideline or guidelines).ti,kf,kw. (138034)
- 43 ((practice or treatment* or clinical) adj guideline*).ab. (54157)
- 44 (CPG or CPGs).ti. (6485)
- 45 consensus*.ti,kf,kw. (35834)
- 46 consensus*.ab. /freq=2 (35195)
- 47 ((critical or clinical or practice) adj2 (path or paths or pathway or pathways or protocol*)).ti,ab,kf,kw. (27297)



- 48 recommendat*.ti,kf,kw. (54726)
- 49 (care adj2 (standard or path or paths or pathway or pathways or map or maps or plan or plans)).ti,ab,kf,kw. (86234)
- 50 (algorithm* adj2 (screening or examination or test or tested or testing or assessment* or diagnosis or diagnoses or diagnosed or diagnosing)).ti,ab,kf,kw. (10620)
- 51 (algorithm* adj2 (pharmacotherap* or chemotherap* or chemotreatment* or therap* or treatment* or intervention*)).ti,ab,kf,kw. (13279)
- 52 or/29-51 (757149)
- 53 20 and 52 (1023)
- 54 limit 20 to yr="2010-2023" (236954)
- 55 exp pituitary neoplasms/ (30406)
- 56 (pituitary adj5 (neoplasm* or cancer* or tumor*r* or adenoma* or carcinoma?)).ab,ti,kf. (25710)
- 57 (hypophysis adj5 (neoplasm* or cancer* or tumor*r* or adenoma* or carcinoma?)).ab,ti,kf. (298)
- 58 (adenohypophysis adj5 (neoplasm* or cancer* or tumor*r* or adenoma* or carcinoma?)).ab,ti,kf. (115)
- 59 (neurohypophysis adj5 (neoplasm* or cancer* or tumor*r* or adenoma* or carcinoma?)).ab,ti,kf. (106)
- 60 (sella turcica adj5 (neoplasm* or cancer* or tumor*r* or adenoma* or carcinoma?)).ab,ti,kf. (302)
- 61 (sellar adj5 (neoplasm* or cancer* or tumor*r* or adenoma* or carcinoma?)).ab,ti,kf. (1425)
- 62 (suprasellar adj5 (neoplasm* or cancer* or tumor*r* or adenoma* or carcinoma?)).ab,ti,kf. (1602)
- 63 (intrasellar adj5 (neoplasm* or cancer* or tumor*r* or adenoma* or carcinoma?)).ab,ti,kf. (421)
- 64 (pituitary adj5 (m#croadenoma? or oncocytoma? or ependydoma? or lymphoma? or plasmacytoma?)).ab,ti,kf. (2979)
- 65 (hypophysis adj5 (m#croadenoma? or oncocytoma? or ependydoma? or lymphoma? or plasmacytoma?)).ab,ti,kf. (17)
- 66 (adenohypophysis adj5 (m#croadenoma? or oncocytoma? or ependydoma? or lymphoma? or plasmacytoma?)).ab,ti,kf. (31)
- 67 (neurohypophysis adj5 (m#croadenoma? or oncocytoma? or ependydoma? or lymphoma? or plasmacytoma?)).ab,ti,kf. (7)
- 68 (sella turcica adj5 (m#croadenoma? or oncocytoma? or ependydoma? or lymphoma? or plasmacytoma?)).ab,ti,kf. (29)
- 69 (sellar adj5 (m#croadenoma? or oncocytoma? or ependydoma? or lymphoma? or plasmacytoma?)).ab,ti,kf. (84)
- 70 (intrasellar adj5 (m#croadenoma? or oncocytoma? or ependydoma? or lymphoma? or plasmacytoma?)).ab,ti,kf. (66)



- 71 (suprasellar adj5 (m#croadenoma? or oncocytoma? or ependydoma? or lymphoma? or plasmacytoma?)).ab,ti,kf. (128)
- 72 (pituitary adj5 (ependymoma? or paraganglioma? or schwannoma? or germinoma? or corticotropinoma? or angiolipoma?)).ab,ti,kf. (381)
- 73 (hypophysis adj5 (ependymoma? or paraganglioma? or schwannoma? or germinoma? or corticotropinoma? or angiolipoma?)).ab,ti,kf. (3)
- 74 (adenohypophysis adj5 (ependymoma? or paraganglioma? or schwannoma? or germinoma? or corticotropinoma? or angiolipoma?)).ab,ti,kf. (0)
- 75 (neurohypophysis adj5 (ependymoma? or paraganglioma? or schwannoma? or germinoma? or corticotropinoma? or angiolipoma?)).ab,ti,kf. (11)
- 76 (sella turcica adj5 (ependymoma? or paraganglioma? or schwannoma? or germinoma? or corticotropinoma? or angiolipoma?)).ab,ti,kf. (9)
- 77 (sellar adj5 (ependymoma? or paraganglioma? or schwannoma? or germinoma? or corticotropinoma? or angiolipoma?)).ab,ti,kf. (76)
- 78 (suprasellar adj5 (ependymoma? or paraganglioma? or schwannoma? or germinoma? or corticotropinoma? or angiolipoma?)).ab,ti,kf. (215)
- 79 (intracellular adj5 (ependymoma? or paraganglioma? or schwannoma? or germinoma? or corticotropinoma? or angiolipoma?)).ab,ti,kf. (55)
- 80 prolactinoma?.ab,ti,kf. (3854)
- 81 somatotropinoma?.ab,ti,kf. (286)
- 82 m#croprolactinoma?.ab,ti,kf. (944)
- 83 craniopharyngioma?.ab,ti,kf. (5119)
- 84 pituicytoma?.ab,ti,kf. (213)
- 85 (nelson adj3 syndrome).ab,ti,kf. (83)
- 86 (adenoma? adj5 lactotroph*).ab,ti,kf. (146)
- 87 (adenoma? adj5 somatotroph*).ab,ti,kf. (491)
- 88 (adenoma? adj5 corticotroph*).ab,ti,kf. (686)
- 89 corticotropinoma?.ab,ti,kf. (137)
- 90 gonadotropinoma?.ab,ti,kf. (70)
- 91 thyrotropinoma?.ab,ti,kf. (67)
- 92 56 or 57 or 58 or 59 or 60 or 61 or 62 or 63 or 64 or 65 or 66 or 67 or 68 or 69 or 70 or 71 or 72 or 73 or 74 or 75 or 76 or 77 or 78 or 79 or 80 or 81 or 82 or 83 or 84 or 85 or 86 or 87 or 88 or 89 or 90 or 91 (35099)
- 93 55 or 92 (42897)



- 94 28 and 93 (1)
- 95 53 and 93 (0)
- 96 54 and 93 (108)



4.2. PICO H. pylori

	Inclusion	Exclusion
Design	Clinical guidelines/ consensus studies Systematic/comprehensive reviews and HTAs	Any other study types
Language	English, Dutch, French, German, Italian, Spanish, Portuguese, Spanish	Any other languages
Publication type	Full studies or reports	Letters to the editor, conference abstracts, posters, editorial reports, presentations, primary studies
Population	Patients (adults or children) with stomach complaints or other need for H. pylori testing	/
Intervention	Testing for H. pylori , invasive or noninvasive, histology with or without IHC	Absence of testing for H. pylori
Comparator	/	/
Attributes	Latest guidelines if updated, otherwise guidelines in the last 10 years	Guidelines older than 10 years or updated within the last 10 years
Recommendation characteristics	Any GRADE	/



4.3. PICO Coeliac Disease

	Inclusion	Exclusion
Design	Clinical guidelines/ consensus studies Systematic reviews and HTAs	Any other study types
Language	English, Dutch, French, German, Italian, Spanish, Portuguese, Spanish	Any other languages
Publication type	Full studies or reports	Letters to the editor, conference abstracts, posters, editorial reports, presentations, primary studies
Population	Adults or children with stomach complaints requiring coeliac disease testing or at high risk of this disease	/
Intervention	Diagnostic tests for coeliac disease	Absence of testing for coeliac disease
Comparator	/	/
Attributes	Latest guidelines if updated, otherwise guidelines in the last 10 years	Guidelines older than 10 years or updated within the last 10 years
Recommendation characteristics	Any GRADE	/



4.4. PICO EM indications

	Inclusion	Exclusion
Design	Clinical guidelines/ consensus studies, Systematic/non-systematic reviews, and HTAs	Any other study types
Language	English, Dutch, French, German, Spanish, Italian, Portuguese	Any other languages
Publication type	Full studies or reports	Letters to the editor, conference abstracts, posters, editorial reports, presentations, primary studies
Population	Patients (adults or children) with suspicion of one of the 5 groups of diagnoses	/
Intervention	EM examination of tissue biopsy (incl. TEM/SEM)	Absence of EM
Comparator	Diagnosis by other methods (e.g. light microscopy, genetic testing), or no comparator	/
Attributes	Latest guidelines if updated, otherwise guidelines in the last 10 years	Guidelines older than 10 years or updated within the last 10 years
Recommendation characteristics	Any GRADE	/



5. QUALITY ASSESSMENT – AGREE II GRD – SUMMARY TABLES

Table 6 – Quality assessment of guidelines included in *H. pylori* literature review

Study ID	Quality guideline development methods	Quality of guideline presentation	Completeness of reporting	Quality guideline recommendations	Overall quality of guideline	Comments
Chey 2017	4	6	4	6	5	No information on stakeholder involvement. Evidence base developed systematically, but no evidence tables available. Recommendations are easily accessible. seem appropriate for the intended patient and consistent with the literature. GRADE used for evaluating the quality of evidence , but no details provided on how the guideline development group interacted to get to recommendations.
Smith 2017	3	5	5	6	4	Experts in the area of gastroenterology and microbiology involved but no mention of patient involvement. PICO-questions developed, but no mention of search strings or link to evidence tables (reproducibility impaired). No summary of recommendations provided, but recommendations easy to find. Recommendations coherent and in line with most international guidelines. Aspects related to implementation have been considered.
Romano 2022	4	5	4	5	5	No information on the stakeholders involved in guideline development. Multiple databases are searched but no search strings provided (authors describe their search as systematic). No evidence tables provided (reproducibility impaired). GRADE used. External validation has been sought. No summary of recommendations provided, but statements are highlighted and information is easy to find. Overall guidelines are in line with others and have been explicitly adapted to the Italian context



Malfertheiner 2022	4	7	5	5	5	No details on the type of stakeholders involved, (only mention they come from 29 different countries). Search described as systematic but no search strategy is reported (impaired reproducibility). Methods to achieve consensus well described. It is well organised. Information easy to find. Agreement and GRADE reported. Process to elicit consensus is well described. No major discrepancies with other guidelines.
Katellaris 2023	1	2	1	4	2	Development methods are impossible to evaluate since there is no description of methodology. Key statements and good practice points are highlighted, but are incomplete. The "cascade" approach meant to get universal guidelines, makes things unclear for the reader. No information on the process, neither on the paper nor on the society's website. Despite its shortages, recommendations seem coherent with international literature.
Jones 2017	6	6	5	6	6	A variety of stakeholders involved, but no patients (or parents). Evidentiary base developed systematically, search syntax provided. Good synopsis of recommendations, clear formulation, easy to find. Process seems reproducible but evidence tables not available to the reader. Recommendations are coherent and seem sound.
Georgopoulos 2020	3	6	3	5	4	Stakeholders include a variety of healthcare professionals and scientists. No patients involved; No systematic literature review to inform these guidelines. No evidence tables provided (reproducibility hindered). Based mostly on consensus. Information easy to access. Recommendations generally consistent with other guidelines, the reflection over the contextualization in the Greek environment is explicit and well argued. The grading of the evidence is sometimes inconsistent.



Garces-Duran 2023	3	3	2	2	3	Little information on the literature review (described as systematic): Search terms, search strategies, PICO of clinical questions and evidence tables not available. Stakeholders are limited to healthcare professionals. No patient involvement. Consensus process clearly described. Information is easy to find, but sometimes instead of recommendations we find statements. Reproducibility is hindered by lack of transparency in evidence retrieval. In instances quotations in the supporting evidence discussion do not correspond to the sources cited. Some discrepancy among recommendations within this same guideline (cfr use of ancillary staining). Some statements do not answer the clinical question (cfr invasive vs non-invasive testing).
El-Serag 2018	3	3	3	5	3	Consensus conference not based on a systematic literature review (hindered reproducibility). Reporting on how consensus was established seems clear. Different stakeholders involved but no patients. Guidelines externally validated. Recommendations relatively easy to find but no comprehensive summary is provided. Statements with internal and external agreement and statements with only internal agreement or none not clearly differentiated. Decision making seems to only be a matter of consensus. Recommendations coherent with other international guidelines.
Batts 2013	2	4	1	3	2	Web-based survey about ancillary staining among the members of GIPS. Results presented. No search strategy is provided, no information on databases, no notion of "systematic" (hindered reproducibility). Working groups limited to pathologists. No description of methods on how consensus was established. Recommendations presented in a table, but in the text, they are not easy to find. Recommendations seem to spring from experience rather than from scientific studies.

**Table 7 – Quality assessment guidelines included in coeliac disease literature review**

Study ID	Quality guideline development methods	Quality of guideline presentation	Completeness of reporting	Quality guideline recommendations	Overall quality of guideline	Comments
Al-Toma 2019	3	7	6	6	5	Developed by the European Society for the Study of Coeliac Disease. Experts and stakeholders specified. No patients involved. The search was described as "extensive", limited to Pubmed. Non-systematic. Key search terms were provided. Guidelines clearly structured and recommendations easy to find. They are presented in boxes with its respective strength and quality of evidence (according to GRADE). Recommendations grouped per subject. Procedure well described (good reproducibility). Information for decision-makers appears complete and relevant. Recommendations coherent with other international guidelines and appropriate for the intended population.
Bai 2017	2	3	2	2	2	It is described as experts from 4 continents providing an update with concepts developed since the previous guideline (2013). No specification of the types of experts or details on the search pursued are provided. Difficult to assess if the recommendations follow the evidence from the literature. Recommendations are presented as algorithms and are easy to find, but no strength or level of quality is provided. Difficult to reproduce since little information provided on methods.
Downey 2015	6	6	7	6	6	Evidence systematically searched. Detailed searches available in an appendix. Full description of all stakeholders consulted. No patients or patient representatives involved. The recommendations are well presented and easy to find. The quality of the evidence they are based on is very clear and follows every recommendation. No strength was attached to the recommendations. Easy to follow and all necessary information available in appendices. Recommendations appear to follow the clinical evidence. The quality of the evidence on which every recommendation is based is clearly presented.



Felber 2014	4	5	6	3	4	Evidence systematically searched but no detailed searches or MESH terms used provided. Experts included expecified. No patient associations appear to have been included in the working group. Recommendations well presented in boxes and easy to find. No common summary is provided. Development procedure well described. Recommendations appear to follow the clinical evidence. Strength is given, but quality assessment of the evidence is lacking.
Husby 2020	4	6	6	4	5	Evidence systematically searched but no detailed searches or MESH terms provided (hindered reproducibility). Description of process provided. Developed by the European Society Paediatric Gastroenterology, Hepatology and Nutrition. No patients or patient associations involved. Recommendations are well presented in boxes and easy to find and present their strength. Quality assessment (risk of bias and GRADE) is provided in appendices, but no agreed level of quality was attached to each recommendation. Recommendations consistent with international guidelines.
Ludvigsson 2014	3	3	5	3	3	Comprehensive search (non-systematic). No detailed search or MESH terms provided (hindered reproducibility). Developed by a multidisciplinary panel. A dietitian and a representative of a patient association involved. Recommendations are well presented in boxes and easy to find and present their strength, but no quality assessment is available. No summary of recommendations is offered. Procedure followed well described. Recommendations in line with those of other international guidelines.
Rubio-Tapia 2023	2	6	2	4	3	No details provided on search strategy, but unlikely to be systematic (low reproducibility). Description of expert group involved, or procedure followed in the guidelines development not detailed. Recommendations well-presented and easy to find (with strength and quality of the evidence by GRADE, as well as level of disagreement). Consistent with other international guidelines.



Zingone 2022	4	6	6	6	6	Evidence searched systematically, but no detailed search or terms provided. Developed by a collaboration between different relevant Italian associations. No patient representatives were involved. Methods for guidelines development described in detail. Recommendations well-presented and summarised in a table. Their strength and quality of the evidence (GRADE) provided. Recommendations are consistent with other international guidelines.
-----------------	---	---	---	---	---	--

Table 8 – Quality assessment guidelines included in EM literature review

Study ID	Quality guideline development methods	Quality of guideline presentation	Completeness of reporting	Quality guideline recommendations	Overall quality of guideline	Comments
Kdigo 2021	6	6	5	6	6	Work Group included experts in adult and paediatric nephrology, pathology, epidemiology, and public health. Cochrane Kidney and Transplant was contracted to conduct systematic evidence review and provide expertise in guideline development methodology. No patients, patient representatives or caregivers were involved. Clinical questions with PICOM format. Systematic searches: RCTs and reviews retrieved from Cochrane Kidney and Transplant Registry of studies. Cochrane Risk of Bias tool was used. No summary table with recommendations. Information on decision-making process not entirely transparent.
Sethi 2016	2	5	2	3	2	Very little info on stakeholders ("renal pathologists and nephrologists"). No mention about a systematic literature review. Recommendations clearly presented in sections although no summary table provided. No information on methods to reach consensus. These are only the results of Phase 1 Delphi. Nephrologist perspective will be gathered in round 2. So here can only conclude on the pathological implications. The aim of this study is classification of GN, not diagnostic tools. So low overall quality in terms of guidance for diagnostic tools.



Deschauer 2021	3	2	2	3	2	Good description of experts involved in the development, including patient representatives. Description of a guidelines based on other existing guidelines (no references provided). Performed a search in PubMed, but no search terms provided (low reproducibility). No clear recommendations as such and not rated in terms of strength and quality of the evidence. Recommendations may be appropriate given the sparse evidence and the fact that they concern a large group of different (rare) diseases, but there is a clear lack of information on the methodology used.
Lucas 2017	7	6	4	6	6	The expert group comprised experts and trainees in the field of PCD from multidisciplinary backgrounds including pulmonologists, ENT, cell scientists, electron microscopists and geneticists. Patient-representatives involved. PICO structure questions. Medline & Embase systematic search. Use of GRADE. Decision-making during Delphi not comprehensively described.
Shapiro 2018	6	6	6	6	6	Committee: pulmonologists (adult and paediatric), genetics, radiology, ENT, neonatology, patients and parents of patients, methodologists. Systematic searches. No summary of recommendations provided. GRADE used for strength of recommendations and quality of evidence. Recommendations and their strength were decided by consensus through anonymous online voting by committee members.